Explore our current clinical trials for heart & vascular:
[Updated: 9/18/24]
Electrophysiology
Status:
Enrolling
Summary:
A Study of Milvexian Versus Apixaban in Participants with Atrial Fibrillation
Description:
A phase 3, Randomized, Double-blind, Study to evaluate the efficacy and safety of Milvexian, an Oral Factor Xia Inhibitor vs. Apixaban in patients with Atrial Fibrillation.
General Cardiology
Status:
Follow-up
Summary:
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial
Description:
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Status:
Follow-up
Summary:
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Description:
This study is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Status:
Enrolling
Summary:
Study of Zilebesiran used as add on therapy with HTN
Description:
A randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of zilebesiran used as add on therapy in adult patients with High CV risk and HTN not adequately controlled by SOC meds.
Heart Failure
Status:
Follow-up
Summary:
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Description:
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Vutrisiran in patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy).
Status:
Enrolling
Summary:
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68
Description:
This is a multicenter, randomized, double‐blind, parallel group, placebo‐controlled trial to evaluate the effect of in‐hospital initiation of Dapagliflozin on clinical outcomes in patients with Heart Failure with reduced Ejection Fraction who have been stabilized during hospitalization for acute Heart Failure.
Status:
Enrolling
Summary:
Study to Evaluate Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific’s Investigational ICM System
Description:
The primary objective of this study is to collect physiological measurement data and heart failure event data that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems. This study will not have pre-defined statistical endpoints. To support the primary objective, diagnostic sensor data will be compared to reference clinical testing data and heart failure decompensation events.
Status
Follow-up
Summary
Reducing Lung CongestIon Symptoms in Advanced Heart Failure (RELIEVE-HF)
Description
This is a prospective, multi-center, 1:1 randomized, patient and observer blinded clinical study, with a Shunt Treatment arm and a non-implant Control arm. The study device, the V-Wave Interartrial Shunt System, includes a permanent implant – the Shunt. The Shunt is placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. By transferring blood from the left to the right atrium, the Shunt is intended to reduce excessive left-sided cardiac filling pressures in patients with advanced Heart Failure.
Interventional Cardiology
Status:
Enrolling
Summary:
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement (COMPLETE TAVR)
Description:
This is a randomized, comparative effectiveness study of staged complete revascularization with Percutaneous Coronary Intervention (PCI) to treat Coronary Artery Disease vs medical management alone in patients with symptomatic aortic valve stenosis undergoing elective transfemoral Transcatheter Aortic Valve Replacement (TAVR).
Status:
Follow-up
Summary:
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts
Description:
This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).
Status:
Follow-up
Summary:
Surveillance Registry for Medtronic Coronary Post-Surveillance
Description:
A registry for the collection of data on coronary percutaneous interventions to help fulfill the new European Medical Devices Regulation requirements.
Status:
Enrolling
Description:
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post approval setting.
Status:
Enrolling
Summary:
Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
Description:
Define ChiL is a sub study of the Define GPS study. This multi-center, prospective, randomized controlled study compares PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system.
Status:
Enrolling
Summary:
Impact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact (IMPROVE)
Description:
This is a prospective, single-blind clinical investigation randomizing subjects to intravascular ultrasound (IVUS)-guided coronary stent implantation vs. angiography-guided coronary stent implantation in a 1:1 ratio.
Status:
Enrolling
Summary:
The DISCOVER INOCA Prospective Multi-center Registry
Description:
The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.
Status:
Enrolling
Summary:
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Description:
A Phase 3, randomized, double blind, placebo controlled, event driven study to demonstrate the efficacy and safety of Milvexian, an Oral Factor Xia Inhibitor, after a recent ACS.
Status:
Enrolling
Description:
A multi-center randomized post-approval evaluation of the delivery of intracoronary hyperoxemic supersaturated oxygen therapy for 60 minutes in anterior acute myocardial infarction patients with successful reperfusion (via PCI) ≤ six hours after symptom onset compared to standard therapy.
Structural
Status:
Enrolling
Description:
Standardized Invasive Hemodynamics for Monitoring Acute and Long Term Valve Performance in Patients with Elevated Gradients Post Transcatheter Aortic Valve Replacement